Activation of peroxisome proliferator-activated receptor-γ downregulates soluble epoxide hydrolase in cardiomyocytes

DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1-dependent mechanism

(2010) Donghong Zhang et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy

(2009) D. Ai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo

(2008) Atsuko Motoki et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Agonists at PPAR-γ suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts

(2008) G-H Hao et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pioglitazone, a Thiazolidinedione Derivative, Attenuates Left Ventricular Hypertrophy and Fibrosis in Salt-Sensitive Hypertension

(2008) Minori NAKAMOTO et al.   HYPERTENSION RESEARCH

Soluble Epoxide Hydrolase Inhibitors Reduce the Development of Atherosclerosis in Apolipoprotein E-Knockout Mouse Model

(2008) Arzu Ulu et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease

(2008) Jan Monti et al.   NATURE GENETICS